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Abstract Escherichia coli gene fimAwas the most frequent
gene that occurred in the intestine of all investigated
groups. All subjects with fimA gene had significantly
higher values of tumor necrosis factor alpha (TNF-α) and
CRP than those with other E. coli genes. There was also a
tendency to increased serum interleukin (IL)-6 levels in
patients carrying the fimA gene; however, no relation was
observed to serum IL-8 and IL-10. Patients with Crohn’s
disease had significantly higher IL-6 than those with
ulcerative colitis (UC) and controls. The highest levels of
TNF-α were detected in the UC group. There were no
significant differences in serum IL-8 and IL-10 between all
three groups. The presence of E. coli gene fimA in the large
bowel of patients with IBD is related to the immunological
activity of the disease which may be important from the
aspect of therapeutical strategy.
Inflammatory bowel diseases (IBD) comprising two forms,
Crohn’s disease (CD) and ulcerative colitis (UC), are
chronically remitting disorders characterized by inflamma-
tion of the gastrointestinal tract. Currently, the etiopatho-
genesis of these disorders is not completely understood,
although chronic relapsing inflammation is considered to be
a result from a dysregulated, aberrant immune response to
intestinal flora in a context of genetic predisposition
(Sanchez-Muñoz et al. 2008; Chamberli and Naser 2006).
Many studies documented an increase in proinflamma-
tory cytokine expression from T lymphocytes, neutrophils,
macrophages, and epithelial cells in patients with IBD;
however, the results about their clinical significance and
relation to clinical activity of CD and UC are controversial
(Fantini et al. 2007; Scaldaferri and Fiocchi 2007). Tumor
necrosis factor alpha (TNF-α) and interleukin (IL)-6 seem
to be most closely associated with clinical and laboratory
activity of the disease (Irving et al. 2005).
There is strong evidence that environmental factors
implicated in the pathogenesis of IBD are bacteria and
their components. Both CD and UC primarily affect
intestinal areas with high bacterial counts. Further evidence
supporting a role of enteric flora in the pathogenesis of IBD
is that treatment with antibiotics and probiotics was found
to be beneficial and could be used to maintain the remission
of the disease (Dignass et al. 2004; Macfarlane et al. 2009).
The most prevalent bacteria in patients with IBD are
Enterobacteriaceae, especially Escherichia coli (Guarner
and Malagelada 2003). Recently, novel genetic classes of E.
coli have been considered to be associated with CD and
UC. Many genes of E. coli were described to be present in
the small and large bowel in healthy humans and patients
with IBD; however, only some of them are supposed to
play a role in the pathogenesis of inflammation. Currently,
there are no data about the clinical significance of these
genes in the pathogenesis of CD and UC as well as their
prevalence in the large bowel of patients with IBD (Dogan
and Simpson 2008).
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DOI 10.1007/s12223-011-0051-zThe aim of this study was to determine the occurrence of
pathogenic E. coli genes in the large bowel of patients with
CD and UC in comparison with control subjects and to
assess their relation to clinical as well as laboratory activity
of the disease.
Subjects and methods
Subjects
Group of patients consisted of 68 subjects with the
diagnosis of inflammatory bowel disease, i.e., CD or UC
(36 men, 32 women), with mean age of 34.5 years (range,
19–72). Thirty-two patients were diagnosed to have
ulcerative colitis (14 men, 18 women; mean age, 37.8 years;
range, 21–72) and 36 had Crohn’s disease (22 men, 14
women; mean age, 31.1 years; range, 19–63).
The diagnosis of IBD was based on clinical symptoms,
laboratory evaluations, and endoscopic finding confirmed
by histological evaluation. None of the patients were in
complete endoscopic remission. Sixteen patients with CD
and 12 patients with UC were treated by antibiotics
(quinolones or metronidazole). The clinical activity of CD
was based on the Crohn’s Disease Activity Index (Best et
al. 1976), and the activity of the ulcerative colitis was based
on the Ulcerative Colitis Disease Activity Index (Schroeder
et al. 1987).
Twenty-eight% (n=10) of the patients with Crohn’s
disease had mild activity, and 72% had moderate activity.
None of them had severe activity. Among the patients with
ulcerative colitis, 25% (n=8) had mild disease activity, 43%
(n=14) had moderate activity, and 32% (n=10) of patients
had severe activity, respectively. Control group consisted of
37 subjects (15 male, 22 female; mean age, 52.4 years;
range, 21–78) with negative colonoscopy. Histological
examinations of the colon specimens were negative in all
these subjects.
Methods
All patients underwent colonoscopic examination after
preparation using 3–4 L of the mineral water (Šaratica,
Slovakia) with high magnesium content. During the
colonoscopy (performed with the colonoscopic device
Olympus Q 145 L), specimens of the colon mucosa were
collected for histological and microbiological evaluation.
Microbiological evaluation
Two mucosal specimens were obtained during colonoscopy
from the surrounding of maximal ulcerative mucosal
lesions. Samples were immediately inserted into a 0.9%
NaCl solution and processed within 1 h after sampling.
Bacteria were isolated after washing, and the biopsy
specimens were homogenized and inoculated into Mac-
Conkey agar and blood agar and cultivated for 24 h at 37°
C. Identification of strains was done based on biochemical
characteristics using Enterotest 16, Entero-Rapid 24
(Lachema, Czech Republic), and some strains were con-
firmed by using identification kits BBL Crystal (Becton
Dickinson, USA). The virulence of E. coli strains was
tested by the phenotype expressions and genes detection.
Examined genes coded factors of virulence in bacterial
genome of tested strains. Polymerase chain reaction (PCR)
was used to detect E. coli genes. One gene was detected by
simplex PCR, while occurrence of other genes was detected
by multiplex PCR.
Preparation of template DNA for PCR Bacteria were
inoculated into LB broth (5 mL), incubated for 24 h at
37°C, and then centrifuged (1,000×g, 10 min). Sediment
was resuspended in 200 μL of sterile distilled water,
incubated for 10 min in water bath at 100°C, and cooled
to laboratory temperature. After an additional 10 min,
fragments of lysed cells were removed by centrifugation
from the lysate. Supernatant was used as a template DNA
for PCR.
Occurrence of the following genes has been estimated:
genes coding for toxin production (α-hemolysin (α-hly),
cytotoxic necrotizing factor (cnf1)), genes coded for
production of invasins (invasin (ipaH), invasin (ial)), genes
coded for production of aerobactin (aerobactin synthesize
(iucC), aerobactin (aer)) and genes coded for surface
properties (fimbrias I-type (fimA), afimbrial adhesin (afa),
S-fimbrias (sfa), P-fimbrias (pap), fimbrial adhesin (bfpA),
intimin (eaeA)). The presence of genes coding for virulence
factors of enterovirulent E. coli is an important marker for
the above strain identification.)
PCR detection of genes encoding virulence factors For
demonstration of virulence genes’ (bfpA, α-hly, cnf1, sfa,
pap, ial, ipaH, eaeA, fimA, iucC, aer) characteristic for
enterovirulent E. coli, the protocol according to Kuhnert et
al. (1997), Yamamoto et al. (1995), and Liptakova et al.
(2001) was used; appropriate bacteria encoding each of the
virulence genes were included as PCR positive controls. E.
coli C600 Rif was used as a negative control.
Detection of PCR products Specific gene products were
detected using electrophoresis. The reaction mixture was
analyzed by electrophoresis on 2.0% agarose gels, and the
reaction products were visualized by staining with ethidium
bromide under UV light.
According to the presence of genes coding for virulence
factors, we have included examined E. coli into enter-
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were included into nonpathogenic strains of commensal
enteric flora.
E. coli strains were not detected in mucosal samples
from nine patients. Some other strains, such as Shigella sp.,
Streptococcus sp, Klebsiella sp., Morganella sp., Serratia
sp., were also found. No bacteria were detected in mucosal
samples of 11 patients (Table 1).
Laboratory evaluations All patients as well as controls
underwent blood sample collection before endoscopy.
Laboratory investigation included the measurement of
serum cytokines, namelyIL-6, IL-8, IL-10 and TNF-α and
serum C-reactive protein (CRP). All cytokines were
measured by ELISA method (ELISA kits, Thermo Scien-
tific; Pierce Biotechnology, USA). CRP was measured by
standard biochemical methods.
Statistical analysis Data are presented as means±SD. An
unpaired t test was used for the demonstration of
differences between two groups, and χ
2 test was used
to assess differences in the prevalence of evaluated
parameters.
Results
Immunological evaluations
Patients with CD had significantly higher serum level of IL-
6 than those with UC (p<0.01) and mildly higher IL-6 than
control subjects that reached a borderline significance (p=
0.05; Table 2). There were no significant differences in
serum levels of IL-8 and IL-10 between all three groups.
Serum TNF-α was the highest in the UC group (p<0.01).
We also detected a tendency to higher TNF-α levels in CD
group; however, it did not reach the statistical significance
in comparison with the control group. Both CD and UC
groups had significantly higher CRP values than controls
with the highest levels in UC group.
Occurrence of E. coli genes in colonic mucosa of patients
with UC, CD, and control subjects
Gene fimA encoding the surface properties was the most
frequent gene that occurred in all the investigated groups,
including the control subjects (Table 3). UC patients had
significantly higher prevalence of iucC gene encoding the
aerobactin in comparison with CD patients. The invasivity
gene IpaH was not detected in both CD and UC patients.
We did not detect significant differences in the prevalence
of other E. coli genes among all three groups.
All subjects with the E. coli gene fimA tended to have
increased serum IL-6 levels (p=0.05). There were no
significant differences in the serum levels of IL-8 and IL-
10 in relation to the presence of various E. coli genes. All
subjects carrying the E. coli gene fimA had significantly
higher values of TNF-α (p<0.01). There were no signifi-
cant differences in serum TNF-α in relation to other E. coli
genes. Moreover, patients with fimA gene had significantly
higher CRP than those with other E. coli genes (p<0.05;
Fig. 1).
Discussion
The relation of inflammatory bowel diseases to the presence
of some strains of E. coli bacteria has been studied during
the last years; however, there are still no data about the
relation of the E. coli genes to the clinical and laboratory
activity of IBD. For that purpose, we evaluated the presence
of some of E. coli genes in relation to the severity of UC or
CD.
Patients with CD and UC had significantly increased
CRP serum level, which is in agreement with previous
studies that showed that CRP serum levels are related to
systemic inflammation. Nevertheless, some studies docu-
Bacterial strain Controls (n=37), % CD (n=36), % UC (n=32), %
E. coli 86.5 80.6 75
Shigella sp. 0 2.7 0
Streptococcus sp. 0 2.7 3.1
Pseudomonas sp. 2.7 0 0
Enterococcus sp. 2.7 0 0
Klebsiella sp. 0 0 3.1
Morganella sp. 0 0 3.1
Serratia sp. 0 0 3.1
Proteus sp. 0 0 3.1
Bacteria not detected 8.1 13.9 9.4
Table 1 Summary of detected
bacterial strains in mucosal
samples
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assessment of clinical activity of IBD (Vermèire et al.
2006; Douda et al. 2006; Florin et al. 2006; Denis et al.
2007).
Bowel inflammation was shown to be characterized by
mucosal infiltration with neutrophils which is associated
with the release of proinflammatory cytokines (Sansonetti
et al. 1999). We also found significantly higher plasma
levels of IL-6 in patients with CD in comparison with those
with UC and control subjects. An increase in IL-6 is
considered to reflect the clinical activity of IBD because
none of the patients were in clinical remission.
This is in agreement with previous studies that found
an increased serum IL-6 level in patients with CD as
compared to UC and controls (Mudter and Neurath
2007). On the other hand, some other authors found that
lamina propria mononuclear cells produce markedly
higher amounts of IL-6 in UC patients than in those with
CD (Reinecker et al. 1993). Because IL-6 was identified to
promote tumor growth, this finding may partially explain
an increased occurrence of colonic cancer in UC. We also
f o u n dh i g h e rl e v e l so fI L - 6i nU Cp a t i e n t sa sc o m p a r e dt o
control subjects which is also in agreement with previous
observations.
There were no significant differences in serum levels of
IL-8 and IL-10 in all three groups. Our results are in
agreement with Nielsen et al. (1997), who reported that IL-
10 concentrations did not differ among UC, CD, and
healthy control subjects. Controversially, Mitsuyama et al.
(2006) found that the concentrations of serum IL-10
increased in patients with UC but not in those with active
CD when compared to normal subjects. This controversial
finding is difficult to explain. Values of IL-10 might be
influenced by the treatment because all of the patients were
treated pharmacologically and were in various stages of
clinical activity. Moreover, the serum levels of IL-10 may
not strictly reflect its mucosal mononuclear production,
which has been demonstrated in in vitro studies to be
increased (Sanchez-Muñoz et al. 2008; Scaldaferri and
Fiocchi 2007).
We also detected a significantly higher serum TNF-α
concentration in patients with UC and its mild increase in
patients with CD. The results are in agreement with
Scaldaferri and Fiocchi (2007) and Mitsuyama et al.
Table 2 Immunological evaluation
Parameter Controls CD UC Significance
Controls vs. CD Controls vs. UC CD vs. UC
IL-6 2.98±0.17 4.58±0.80 2.41±0.19 p=0.05 ns p<0.01
IL-8 12.1±3.21 9.54±1.47 15.6±3.00 ns ns ns
IL-10 7.92±2.08 7.32±1.10 7.06±1.40 ns ns ns
TNF-α 24.5±3.25 47.8±9.09 75.5±19.22 ns p<0.01 ns
CRP 4.40±0.84 25.5±4.60 41.3±7.27 p<0.01 p<0.01 p<0.05
For numbers of CD, UC samples, and controls, see Table 1
ns not significant
E. coli gene Control CD UC Significance
Controls vs. CD Controls vs. UC CD vs. UC
ipaH 10 0 – – –
iucC 17 10 18 ns ns p<0.01
fimA 28 23 22 ns ns ns
α-hly 0 3 5 n sn sn s
afa 2 6 1 n sn sn s
aer 16 16 14 ns ns ns
cnf1 4 8 10 ns ns ns
sfa 7 9 4 n sn sn s
pap 10 13 10 ns ns ns
bfpA 00 0 –– –
eae 01 5 –– ns
Table 3 Occurrence of E. coli
genes in colonic mucosa of
patients with UC, CD, and con-
trol subjects
For numbers of CD, UC sam-
ples, and controls, see Table 1
ns not significant
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as well as in mucosa in patients with IBD, which reflects
the clinical activity of the disease.
In our study, the most prevalent gene was the fimA
encoding the superficial properties of bacteria. It is
supposed to participate in initiation and persistence of
chronic inflammation by uncontrolled production of proin-
flammatory cytokines. Our findings are supported by
results of Boudeau et al. (2001) who evaluated the
relationship between fimbriae I, encoded by the gene fimA,
and secretion of proinflammatory cytokines; they con-
firmed that the adherence of fimbriae I initiates the
production of proinflammatory cytokines. In healthy
humans, the significance of this mechanism is unknown.
Genes eae, encoding aerobactin, and iuC,e n c o d i n g
areobactinsyntase, were found to occur less frequently. We
also demonstrated significantly higher levels of TNF-α, IL-
6, and CRP in patients with E. coli carrying the gene fimA.
E. coli is the predominant facultative aerobic inhabitant
of human intestine and part of normal enteric flora. There is
growing evidence that E. coli is more prevalent in patients
with IBD in comparison to control subjects (e.g., Martin et
al. 2004). For example, some studies demonstrated that CD
is associated with invasive E. coli strains since 29% of CD
patients were infected with intramucosal E. coli in
comparison with 9% of control subjects (Mitsuyama et al.
2006). Sasaki et al. (2007) showed that E. coli isolated from
IBD patients induced significantly higher TNF-α expres-
sion in macrophage cell cultures in vitro. This is also
supported by our study; we showed that some E. coli genes,
Fig. 1 Plasma levels of IL-6,
IL-8, IL-10, TNF-α, and CRP
in all investigated groups in
relation to the presence of most
frequently occurring E. coli
genes (afa, eae, cnf1, fimA);
white columns negative, gray
columns positive
Folia Microbiol (2011) 56:367–372 371fimA in particular, were associated with the laboratory
inflammatory activity, i.e., higher levels of TNF-α, IL-6, as
well as CRP.
To the best of our knowledge, this is the first clinical
study evaluating the relationship between fimA gene of E.
coli and laboratory markers of inflammation in patients
with Crohn’s disease and ulcerative colitis, demonstrating
that the presence of E. coli gene fimA is related to the
laboratory activity of the disease.
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